Evolus Strengthens Aesthetic Neurotoxin Market Position with Jeuveau® and New Product Launches

Evolus Reinforces Its Position in the Aesthetic Neurotoxin Market

Evolus, Inc., a Newport Beach-based performance beauty company, is poised to enhance its presence in the aesthetic neurotoxin market. The company is set to present at the upcoming Stifel Healthcare Conference in New York City on November 19, where it will share insights into its innovative product offerings and growth strategy. Central to Evolus's mission is its flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), which distinguishes itself as the first neurotoxin exclusively dedicated to aesthetic applications. Utilizing advanced Hi-Pure™ technology, Jeuveau® offers a refined solution for cosmetic procedures, targeting the evolving demands of beauty consumers.

In addition to Jeuveau®, Evolus is strategically expanding its product portfolio by securing exclusive distribution rights for two innovative products: Evolysse™ in the U.S. and Estyme® in Europe. Both products—injectable hyaluronic acid gels—are currently undergoing late-stage regulatory approval, with potential market launches anticipated as early as 2025. This expansion signifies Evolus’s commitment to becoming a comprehensive multi-product aesthetics company and showcases its ability to adapt to market trends and consumer preferences.

Evolus's growth strategy is underpinned by a customer-centric business model that leverages innovative digital platforms to engage with the next generation of beauty consumers. By focusing on aesthetic treatments that resonate with the desires of modern clients, Evolus aims to strengthen its market position and establish itself as a leader in the aesthetics industry. As the company continues to evolve, its dedication to quality and innovation remains at the forefront of its initiatives.

In addition to its product advancements, Evolus is enhancing its visibility through strategic presentations and digital engagement. The upcoming conference presentation will be accessible via the Investor Relations section of the Evolus website, allowing stakeholders to stay informed about the company's trajectory and future plans. The presentation will also be available for replay for 90 days, ensuring that interested parties have ongoing access to the information shared.

With trademarks secured for key products like Jeuveau® and Nuceiva®, Evolus is laying a solid foundation for its ambitious growth plans. The company's focus on innovation and regulatory approvals for new products positions it to meet the needs of a dynamic and competitive market, ultimately aiming to redefine the standards in the aesthetic neurotoxin sector.